Cognito Therapeutics has reached its enrolment goal for the HOPE Study investigating the Spectris AD system for Alzheimer's disease (AD).

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Researchers at McMaster University, Cleveland Clinic and Case Comprehensive Cancer Center have uncovered how a protein long ...

Smaller, shallow brain folds in the posteromedial cortex show greater thinning with age and Alzheimer’s disease, and their ...

A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset ...

A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset ...

New indication added for selection of patients for amyloid-directed therapiesQuantitative image analysis addedPrevious limitations of use removed Amyloid, a naturally occurring protein, can accumulate ...

A new tool developed by researchers can estimate how fast someone is aging by analyzing a single MRI brain scan, predicting ...

Scientists found that brain cells can tap a hidden sugar stash to clean up the toxic proteins behind Alzheimer’s. By kick-starting an enzyme called GlyP, they reroute stored sugar into a protective ...

Cognito Therapeutics Completes Enrollment in HOPE Pivotal Study of Spectris™ AD Therapy for the Treatment of Patients with Alzheimer’s Disease ...